Gram-Positive Bacterial Infections Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Size, Share & Trends, Drivers, Restraints, Opportunities, Manufacturer, Applications, And Segments

  • AMR-1065072
  • May 2021
  • Pharmaceuticals
  • 115 Pages
The Gram-Positive Bacterial Infections Market research report comprises of an overall in depth-analysis such as market drivers, opportunities, restraints, latest developments and trends, segmentation of the market, competitive analysis, global as well as regional analysis by showcasing how each of these factors can improve the further growth of the market on an overall perspective. The report also showcases the overall market value which includes the historic data (2018-2019) and forecast data (2020-2028) generated through the revenue (USD Mn)
 
Report Parameters Details of Parameter
Market Size xx Million
Based Year 2020
Forecast Period Covered 2020 – 2028
Units for value Revenue in USD million and CAGR from 2020 to 2028
Covered Segments Component, Types, Applications, End-Users, and more.
Companies Covered ALLERGAN, AstraZeneca, Bayer AG, GlaxoSmithKline plc., Merck & Co., Inc., NovaBiotics Ltd, Novartis AG, Pfizer Inc., Sanofi, Theravance Biopharma
Region Covered North America, Europe, Asia Pacific, Latin America, Middle East and Africa

COVID-19 Coverage
With the beginning of the COVID-19 pandemic in early 2020, all major economies around the world enforced severe lockdown restrictions to curb the spread of the virus. Apart from a few sectors such as healthcare and related essential services, most of the industries suffered tremendously due to inability to function in a normal fashion. Moreover, even some of the essential sectors suffered due to delays caused by supply chain disruptions and other travel complexities. However, with massive vaccination drives in most of the developed economies, some of the economies across the world experienced economic recovery from 2021. The Gram-Positive Bacterial Infections market is expected to gain momentum in such economies and probably recover some of the losses inflicted in the year 2020. With continued efforts towards curbing the virus in the developing economies, the Gram-Positive Bacterial Infections market is expected to attain Pre COVID-19 levels by mid-2022.

Gram-Positive Bacterial Infections Report’s Assessment
The research report is formulated such that it offers a deep understating on the market drivers that are assimilating the growth of the market, the market opportunities that are going to provide future growth factors for the market and the market restraints which showcase the reasons as to why the market can get hampered and dissimilated. All these factors are considered keeping in view the historic and forecast analysis which can enlighten the above mentioned factors.

Thereby at a glance a reader can understand all the factors and prospects of the Gram-Positive Bacterial Infections market and how it can assimilate and dissimilate based on each of the factors and figures mentioned in the report

Gram-Positive Bacterial Infections Market Competitive and Premeditated Analysis
In the Gram-Positive Bacterial Infections report major factors such latest tactical developments, competitors, research and development, participation of each region in the market and the competition among them, the latest news regarding company acquisitions and product launch, revenue of the competitors as well as the key offerings they provide all these factors are mentioned in the report with reasons to justify and understand them in depth.

The readers and purchaser of the Gram-Positive Bacterial Infections research report can gain a comprehensive understanding of the market competition, the revenue of each major players and their contribution towards the market, attractive proposition analysis is provided in the report which sub divides the segments with respect to the largest segment that has contributed to the market growth and the fastest growing segment based on the size of the market as well as its overall appeal.
 
Major Key Players for Global Gram-Positive Bacterial Infections Market:
The Gram-Positive Bacterial Infections market research report offers the company profile of major key players including progress trends, competitive landscape breakdown, and key in regions development status. ALLERGAN, AstraZeneca, Bayer AG, GlaxoSmithKline plc., Merck & Co., Inc., NovaBiotics Ltd, Novartis AG, Pfizer Inc., Sanofi, Theravance Biopharma

The Gram-Positive Bacterial Infections market report showcases vast potentials of growth and assimilation which is going to provide the industry numerous opportunities to grow and generate revenue by understanding the segments and which segment is a potential part to increase the disposable income in the present and upcoming years.

Gram-Positive Bacterial Infections Market Segmentation Analysis:
Each of the segment is explained in brief along with the revenue it generates for the market based on the historic and forecast data by highlighting the largest segment and the fastest growing segment with reasons to justify it.

The Global segmentation of the Gram-Positive Bacterial Infections market:
by Disease
Methicillin-Resistant Staphylococcus Aureus
MRSA
Pneumonia
Sepsis
Sinusitis
Skin Disorders and Other Diseases
Drug Type
Antibiotic
Antifungal and Others
Route of Administration
Enteral
Parenteral and Others
Distribution Channel
Hospital Pharmacies
Drug Stores and Retail Pharmacies and Other Distribution Channels

Regional Analysis of the Gram-Positive Bacterial Infections market:
The Gram-Positive Bacterial Infections market is dived based on different regions such as North America, Europe, Asia Pacific, Latin America and the Middle East and Africa. And the analysis of each region is provided by highlighting the largest contribution region, the fastest growing region and the factors that is keeping the market active in the other regions is also mentioned in depth. Each regional segment also comprises of the revenue each segment holds in a specific region with reasons to justify the values.

By Regions:
  • North America (U.S and Canada)
  • Europe (U.K., Germany and France)
  • Asia Pacific (China, India and Japan)
  • Latin America (Mexico and Brazil)
  • Middle East and Africa (GCC Countries and South Africa)
 


Major Factors Included and highlighted in the Gram-Positive Bacterial Infections report are as follows:
  • The overall market value along with historic and future data analysis.
  • The Growth drivers, opportunities and restraints are mention in detail.
  • The size of the entire Gram-Positive Bacterial Infections market on a global perspective.
  • The CAGR value of the overall market from 2020 to 2028.
  • COVID-19 impact on the Gram-Positive Bacterial Infections market and how it is coping up with the situation.
  • Major competitors and their contribution towards the market.
  • The segmentation analysis is included which provides a clear picture of the market bifurcation.
  • Tables and graphs that can easily been understood at a glance
  • Latest trends and news related to the Gram-Positive Bacterial Infections market is included in the report.
Key Analytical Areas:
The report aims to offer a complete solution to various businesses operating in the Gram-Positive Bacterial Infections market in making strategic decisions based on credible information and actionable insights. Thereby, the report covers various aspects of your requirements such as industry overview, market dynamics, regional analysis and competitive landscape. The report aims to provide insights to businesses in the Gram-Positive Bacterial Infections market for numerous purposes such as:

     1. Strategic Decision Making:
With the help of this report, key decision makers can quickly analyze and identify growth opportunities in terms of numerous segments across various geographical regions. Thereby, this report enables organizations to identify and make strategic investments in specific market segments in order to gain maximum return on investment.

     2. Actionable Insights:
The report offers a deep dive into how companies are leveraging market conditions to make the most in the Gram-Positive Bacterial Infections market. Thereby, the report offers numerous actionable insights into the best practices and key success factors relevant in the Gram-Positive Bacterial Infections market. Using the insights included in the report, businesses can make quick decisions to achieve success in business operations.

     3. Competitive Snapshot:
In addition, to detailed information on the companies operating in the Gram-Positive Bacterial Infections market, the report also includes a competitive snapshot of all the companies covered in the report. Thereby, this offers a visual representation of how all the companies stand comparatively based on their competencies, geographic presence, market hold, years of operations, employee and financial strength, among others.

Manufacturers and Segments

  • ALLERGAN
  • AstraZeneca
  • Bayer AG
  • GlaxoSmithKline plc.
  • Merck & Co., Inc.
  • NovaBiotics Ltd
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Theravance Biopharma
  • Methicillin-Resistant Staphylococcus Aureus
  • MRSA
  • Hospital Pharmacies
  • Drug Stores and Retail Pharmacies and Other Distribution Channels

Have query on this report?

Make an Enquiry
1. Preface
     1.1. Report Scope and Description
     1.2. Research Methodology
          1.2.1. Phase I-Secondary Research
          1.2.2. Phase II-Primary Research
          1.2.3. Phase II-Expert Panel Review
          1.2.4. Assumptions
          1.2.5. Approach Adopted

2. Executive Summarysegment Form
     2.1. Global Gram-Positive Bacterial Infections Market Snapshot
          2.1.1. Global Gram-Positive Bacterial Infections Market By Disease,2019
               2.1.1.1.Methicillin-Resistant Staphylococcus Aureus
               2.1.1.2.MRSA
          2.1.2. Global Gram-Positive Bacterial Infections Market By Distribution Channel,2019
               2.1.2.1.Hospital Pharmacies
               2.1.2.2.Drug Stores and Retail Pharmacies and Other Distribution Channels
          2.1.3. Global Gram-Positive Bacterial Infections Market By End-use,2019
          2.1.4. Global Gram-Positive Bacterial Infections Market By Geography,2019

3. Global Gram-Positive Bacterial Infections Market Dynamics
     3.1. Market Overview
     3.2. Market Inclination Insights Analysis
     3.3. Drivers
     3.4. Challenges
     3.5. Future Prospects
     3.6. Impact Analysis of Drivers and Challenges During the Forecast Period, (2020-2028)

4. Global Gram-Positive Bacterial Infections Market Size (US$), By Disease, 2018 – 2028 
     4.1. Overview
          4.1.1. Market Share Analysis By Disease, 2019 vs.2028
          4.1.2. Attractive Investment Proposition By Disease, 2020
     4.2. Global Gram-Positive Bacterial Infections Market Size (US$), By Disease, 2018 – 2028

5. Global Gram-Positive Bacterial Infections Market Size (US$), By Distribution Channel, 2018 – 2028 
     5.1. Overview
          5.1.1. Market Share Analysis By Distribution Channel, 2019 vs.2028
          5.1.2. Attractive Investment Proposition By Distribution Channel, 2020
     5.2. Global Gram-Positive Bacterial Infections Market Size (US$), By Distribution Channel, 2018 – 2028

6. Global Gram-Positive Bacterial Infections Market Size (US$), By End-use, 2018 – 2028 
     6.1. Overview
          6.1.1. Market Share Analysis By End-use, 2019 vs.2028
          6.1.2. Attractive Investment Proposition By End-use, 2020
     6.2. Global Gram-Positive Bacterial Infections Market Size (US$), By End-use, 2018 – 2028

7. Global Gram-Positive Bacterial Infections Market Size (US$), By Geography, 2018 – 2028
     7.1. Overview
          7.1.1. Market Share Analysis by Geography, 2019 vs. 2028
          7.1.2. Attractive Investment Proposition by Geography, 2020
     7.2. North America Gram-Positive Bacterial Infections Market Analysis, 2018 – 2028 
          7.2.1. North America Gram-Positive Bacterial Infections Market Size (US$), By Country, 2018 – 2028 
               7.2.1.1. U.S.
               7.2.1.2. Canada
          7.2.2. North America Gram-Positive Bacterial Infections Market Size (US$), By Disease, 2018 – 2028
          7.2.3. North America Gram-Positive Bacterial Infections Market Size (US$), By Distribution Channel, 2018 – 2028
          7.2.4. North America Gram-Positive Bacterial Infections Market Size (US$), By End-use, 2018 – 2028
     7.3. Europe Gram-Positive Bacterial Infections Market Analysis, 2018 – 2028 
          7.3.1.  Europe Gram-Positive Bacterial Infections Market Size (US$), By Country, 2018 – 2028 
               7.3.1.1. U.K.
               7.3.1.2. Germany
               7.3.1.3. France
               7.3.1.4. Rest of Europe
          7.3.2. Europe Gram-Positive Bacterial Infections Market Size (US$), By Disease, 2018 – 2028
          7.3.3. Europe Gram-Positive Bacterial Infections Market Size (US$), By Distribution Channel, 2018 – 2028
          7.3.4. Europe Gram-Positive Bacterial Infections Market Size (US$), By End-use, 2018 – 2028
     7.4. Asia Pacific Gram-Positive Bacterial Infections Market Analysis , 2018 – 2028
          7.4.1.  Asia Pacific Gram-Positive Bacterial Infections Market Size (US$), By Country, 2018 – 2028 
               7.4.1.1. China
               7.4.1.2. Japan
               7.4.1.3. India
               7.4.1.4. Rest of Asia Pacific
          7.4.2. Asia Pacific Gram-Positive Bacterial Infections Market Size (US$), By Disease, 2018 – 2028
          7.4.3. Asia Pacific Gram-Positive Bacterial Infections Market Size (US$), By Distribution Channel, 2018 – 2028
          7.4.4. Asia Pacific Gram-Positive Bacterial Infections Market Size (US$), By End-use, 2018 – 2028
     7.5. Latin America Gram-Positive Bacterial Infections Market Analysis, 2018 – 2028 
          7.5.1.  Latin America Gram-Positive Bacterial Infections Market Size (US$), By Country, 2018 – 2028 
               7.5.1.1. Brazil
               7.5.1.2. Mexico
               7.5.1.3. Rest of Latin America
          7.5.2. Latin America Gram-Positive Bacterial Infections Market Size (US$), By Disease, 2018 – 2028
          7.5.3. Latin America Gram-Positive Bacterial Infections Market Size (US$), By Distribution Channel, 2018 – 2028
          7.5.4. Latin America Gram-Positive Bacterial Infections Market Size (US$), By End-use, 2018 – 2028
     7.6. Middle East & Africa (MEA) Gram-Positive Bacterial Infections Market Analysis, 2018 – 2028 
          7.6.1.  MEA Gram-Positive Bacterial Infections Market Size (US$), By Region, 2018 – 2028 
               7.6.1.1. GCC Countries
               7.6.1.2. South Africa
               7.6.1.3. Rest of MEA
          7.6.2. MEA Gram-Positive Bacterial Infections Market Size (US$), By Disease, 2018 – 2028
          7.6.3. MEA Gram-Positive Bacterial Infections Market Size (US$), By Distribution Channel, 2018 – 2028
          7.6.4. MEA Gram-Positive Bacterial Infections Market Size (US$), By End-use, 2018 – 2028

8. Company Profiles
     8.1. Competitive Analysis 
     8.2. Market Positioning of Key Vendors 
     8.3. Key Strategies adopted by the Leading Players
     8.4. Key Gram-Positive Bacterial Infections Providers
        8.4.1 ALLERGAN
                8.4.1.1 Business Description
                8.4.1.2 ALLERGAN Geographic Operations
                8.4.1.3 ALLERGAN Financial Information
                8.4.1.4 ALLERGAN Product Positions/Portfolio
                8.4.1.5 ALLERGAN Key Developments
        8.4.2 AstraZeneca
                8.4.2.1 Business Description
                8.4.2.2 AstraZeneca Geographic Operations
                8.4.2.3 AstraZeneca Financial Information
                8.4.2.4 AstraZeneca Product Positions/Portfolio
                8.4.2.5 AstraZeneca Key Developments
        8.4.3 Bayer AG
                8.4.3.1 Business Description
                8.4.3.2 Bayer AG Geographic Operations
                8.4.3.3 Bayer AG Financial Information
                8.4.3.4 Bayer AG Product Positions/Portfolio
                8.4.3.5 Bayer AG Key Developments
        8.4.4 GlaxoSmithKline plc.
                8.4.4.1 Business Description
                8.4.4.2 GlaxoSmithKline plc. Geographic Operations
                8.4.4.3 GlaxoSmithKline plc. Financial Information
                8.4.4.4 GlaxoSmithKline plc. Product Positions/Portfolio
                8.4.4.5 GlaxoSmithKline plc. Key Developments
        8.4.5 Merck & Co., Inc.
                8.4.5.1 Business Description
                8.4.5.2 Merck & Co., Inc. Geographic Operations
                8.4.5.3 Merck & Co., Inc. Financial Information
                8.4.5.4 Merck & Co., Inc. Product Positions/Portfolio
                8.4.5.5 Merck & Co., Inc. Key Developments
        8.4.6 NovaBiotics Ltd
                8.4.6.1 Business Description
                8.4.6.2 NovaBiotics Ltd Geographic Operations
                8.4.6.3 NovaBiotics Ltd Financial Information
                8.4.6.4 NovaBiotics Ltd Product Positions/Portfolio
                8.4.6.5 NovaBiotics Ltd Key Developments
        8.4.7 Novartis AG
                8.4.7.1 Business Description
                8.4.7.2 Novartis AG Geographic Operations
                8.4.7.3 Novartis AG Financial Information
                8.4.7.4 Novartis AG Product Positions/Portfolio
                8.4.7.5 Novartis AG Key Developments
        8.4.8 Pfizer Inc.
                8.4.8.1 Business Description
                8.4.8.2 Pfizer Inc. Geographic Operations
                8.4.8.3 Pfizer Inc. Financial Information
                8.4.8.4 Pfizer Inc. Product Positions/Portfolio
                8.4.8.5 Pfizer Inc. Key Developments
        8.4.9 Sanofi
                8.4.9.1 Business Description
                8.4.9.2 Sanofi Geographic Operations
                8.4.9.3 Sanofi Financial Information
                8.4.9.4 Sanofi Product Positions/Portfolio
                8.4.9.5 Sanofi Key Developments
        8.4.10 Theravance Biopharma
                8.4.10.1 Business Description
                8.4.10.2 Theravance Biopharma Geographic Operations
                8.4.10.3 Theravance Biopharma Financial Information
                8.4.10.4 Theravance Biopharma Product Positions/Portfolio
                8.4.10.5 Theravance Biopharma Key Developments

LIST OF TABLES

TABLE 1 Market Snapshot: Global Gram-Positive Bacterial Infections Market 
TABLE 2 Impact Indicators 
TABLE 3 Impact Analysis of Drivers and Restraints 
TABLE 4 North America Gram-Positive Bacterial Infections Market Revenue, By Disease, 2018 – 2028 (US$ Mn) 
TABLE 5 North America Gram-Positive Bacterial Infections Market Revenue, By Distribution Channel, 2018 – 2028 (US$ Mn) 
TABLE 6 North America Gram-Positive Bacterial Infections Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 7 Europe Gram-Positive Bacterial Infections Market Revenue, By Disease, 2018 – 2028 (US$ Mn) 
TABLE 8 Europe Gram-Positive Bacterial Infections Market Revenue, By Distribution Channel, 2018 – 2028 (US$ Mn) 
TABLE 9 Europe Gram-Positive Bacterial Infections Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 10 Asia Pacific Gram-Positive Bacterial Infections Market Revenue, By Disease, 2018 – 2028 (US$ Mn) 
TABLE 11 Asia Pacific Gram-Positive Bacterial Infections Market Revenue, By Distribution Channel, 2018 – 2028 (US$ Mn) 
TABLE 12 Asia Pacific Gram-Positive Bacterial Infections Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 13 Latin America Gram-Positive Bacterial Infections Market Revenue, By Disease, 2018 – 2028 (US$ Mn) 
TABLE 14 Latin America Gram-Positive Bacterial Infections Market Revenue, By Distribution Channel, 2018 – 2028 (US$ Mn) 
TABLE 15 Latin America Gram-Positive Bacterial Infections Market Revenue, By End-use, 2018 – 2028 (US$ Mn)
TABLE 16 MEA Gram-Positive Bacterial Infections Market Revenue, By Disease, 2018 – 2028 (US$ Mn) 
TABLE 17 MEA Gram-Positive Bacterial Infections Market Revenue, By Distribution Channel, 2018 – 2028 (US$ Mn) 
TABLE 18 MEA Gram-Positive Bacterial Infections Market Revenue, By End-use, 2018 – 2028 (US$ Mn)

LIST OF FIGURES

FIG. 1 Global Gram-Positive Bacterial Infections: Market Segmentation 
FIG. 2 Global Gram-Positive Bacterial Infections Market: Research Methodology 
FIG. 3 Top-Down and Bottom-up Approach 
FIG. 4 Global Gram-Positive Bacterial Infections Market, By Disease, 2019 (US$ Mn) 
FIG. 5 Global Gram-Positive Bacterial Infections Market, By Distribution Channel, 2019 (US$ Mn) 
FIG. 6 Global Gram-Positive Bacterial Infections Market, By End-use, 2019 (US$ Mn) 
FIG. 7 Global Gram-Positive Bacterial Infections Market, By Geography, 2019 (US$ Mn) 
FIG. 8 Global Gram-Positive Bacterial Infections Market Revenue and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG. 9 Attractive Investment Proposition 
FIG. 10 Market Positioning of Key Gram-Positive Bacterial Infections Providers, 2019
FIG. 11 Global Gram-Positive Bacterial Infections Market Revenue Contribution, By Disease, 2019 & 2028 (Value %) 
FIG. 12 Global Gram-Positive Bacterial Infections Market Revenue Contribution, By Distribution Channel, 2019 & 2028 (Value %) 
FIG. 13 Global Gram-Positive Bacterial Infections Market Revenue Contribution, By End-use, 2019 & 2028 (Value %) 
FIG. 14 North America Gram-Positive Bacterial Infections Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 15 Europe Gram-Positive Bacterial Infections Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 16 Asia Pacific Gram-Positive Bacterial Infections Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 17 Latin America Gram-Positive Bacterial Infections Market Revenue, 2018 – 2028, (US$ Mn)
FIG. 18 MEA Gram-Positive Bacterial Infections Market Revenue, 2018 – 2028, (US$ Mn)

Key Takeaways:

1. Market value and estimate of the Gram-Positive Bacterial Infections market for the period from 2020 to 2028
2. Compounded annual growth rate (CAGR%) for individual segments in various regional markets for a period from 2020 to 2028
3. Value chain analysis
4. Market share study combined with competitive landscape of major players
5. Profiles of major market players covering overall business operations, geographic occurrence, product portfolio, financial status and news coverage 

List of Tables

TABLE  Market Snapshot: Global Gram-Positive Bacterial Infections Market
TABLE  Impact Pointers
TABLE  Impact Analysis of Drivers and Restraints
TABLE  North America Gram-Positive Bacterial Infections Market Value, By Segment1, 2018 – 2028
TABLE  North America Gram-Positive Bacterial Infections Market Value, By Segment2, 2018 – 2028
TABLE  North America Gram-Positive Bacterial Infections Market Value, By Country, 2018 – 2028
TABLE  Europe Gram-Positive Bacterial Infections Market Value, By Segment1, 2018 – 2028
TABLE  Europe Gram-Positive Bacterial Infections Market Value, By Segment2, 2018 – 2028
TABLE  Europe Gram-Positive Bacterial Infections Market Value, By Country, 2018 – 2028
TABLE  Asia Pacific Gram-Positive Bacterial Infections Market Value, By Segment1, 2018 – 2028
TABLE  Asia Pacific Gram-Positive Bacterial Infections Market Value, By Segment2, 2018 – 2028
TABLE  Asia Pacific Gram-Positive Bacterial Infections Market Value, By Country, 2018 – 2028
TABLE  Latin America Gram-Positive Bacterial Infections Market Value, By Segment1, 2018 – 2028
TABLE  Latin America Gram-Positive Bacterial Infections Market Value, By Segment2, 2018 – 2028
TABLE  Latin America Gram-Positive Bacterial Infections Market Value, By Country, 2018 – 2028
TABLE  MEA Gram-Positive Bacterial Infections Market Value, By Segment1, 2018 – 2028
TABLE  MEA Gram-Positive Bacterial Infections Market Value, By Segment2, 2018 – 2028
TABLE  MEA Gram-Positive Bacterial Infections Market Value, By Country, 2018 – 2028
TABLE  ALLERGAN: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  AstraZeneca: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Bayer AG: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  GlaxoSmithKline plc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Merck & Co., Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  NovaBiotics Ltd: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Novartis AG: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Pfizer Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Sanofi: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Theravance Biopharma: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
 

List of Figures

FIG.  Global Gram-Positive Bacterial Infections Market: Research Methodology
FIG.  Top-Down and Bottom Up Approach
FIG.  Global Gram-Positive Bacterial Infections Market, By Segment1, 2019 (US$ Mn)
FIG.  Global Gram-Positive Bacterial Infections Market, By Segment2, 2019 (US$ Mn)
FIG.  Global Gram-Positive Bacterial Infections Market, By Geography, 2019 (US$ Mn)
FIG.  Global Gram-Positive Bacterial Infections Market Value and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG.  Attractive Investment Proposition
FIG.  Market Positioning of Key Gram-Positive Bacterial Infections Providers, 2016
FIG.  Global Gram-Positive Bacterial Infections Market Value Share, By Segment1, 2019 & 2028 (% Value)
FIG.  Global MRSA Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Gram-Positive Bacterial Infections Market Value Share, By Segment2, 2019 & 2028 (% Value)
FIG.  Global Drug Stores and Retail Pharmacies and Other Distribution Channels Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Market Value, 2018 – 2028, (US$ Mn)
FIG.  U.S. Gram-Positive Bacterial Infections Market Value, 2018 – 2028, (US$ Mn)
FIG.  Canada Gram-Positive Bacterial Infections Market Value, 2018 – 2028, (US$ Mn)
FIG.  UK Gram-Positive Bacterial Infections Market Value, 2018 – 2028, (US$ Mn)
FIG.  Germany Gram-Positive Bacterial Infections Market Value, 2018 – 2028, (US$ Mn)
FIG.  France Gram-Positive Bacterial Infections Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Europe Gram-Positive Bacterial Infections Market Value, 2018 – 2028, (US$ Mn)
FIG.  China Gram-Positive Bacterial Infections Market Value, 2018 – 2028, (US$ Mn)
FIG.  Japan Gram-Positive Bacterial Infections Market Value, 2018 – 2028, (US$ Mn)
FIG.  India Gram-Positive Bacterial Infections Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Asia Pacific Gram-Positive Bacterial Infections Market Value, 2018 – 2028, (US$ Mn)
FIG.  Mexico Gram-Positive Bacterial Infections Market Value, 2018 – 2028, (US$ Mn)
FIG.  Brazil Gram-Positive Bacterial Infections Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Latin America Gram-Positive Bacterial Infections Market Value, 2018 – 2028, (US$ Mn)
FIG.  GCC Countries Gram-Positive Bacterial Infections Market Value, 2018 – 2028, (US$ Mn)
FIG.  South Africa Gram-Positive Bacterial Infections Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of MEA Gram-Positive Bacterial Infections Market Value, 2018 – 2028, (US$ Mn)